The stock of Unilife Corp (NASDAQ:UNIS) reached all time low today, Sep, 30 and still has $1.88 target or 11.00% below today’s $2.11 share price. This indicates more downside for the $35.27M company. This technical setup was reported by Barchart.com. If the $1.88 PT is reached, the company will be worth $3.88M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 184,127 shares traded hands or 146.15% up from the average. Unilife Corp (NASDAQ:UNIS) has declined 76.26% since February 26, 2016 and is downtrending. It has underperformed by 86.69% the S&P500.
Unilife Corp (NASDAQ:UNIS) Ratings Coverage
Out of 3 analysts covering Unilife Corporation (NASDAQ:UNIS), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Unilife Corporation has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Monday, January 4 by Griffin Securities. Jefferies downgraded Unilife Corp (NASDAQ:UNIS) on Thursday, August 6 to “Hold” rating. The stock of Unilife Corp (NASDAQ:UNIS) earned “Neutral” rating by Piper Jaffray on Tuesday, March 15. On Tuesday, September 15 the stock rating was maintained by Piper Jaffray with “Overweight”. The stock has “Buy” rating given by Griffin Securities on Wednesday, September 16. The firm has “Hold” rating by Griffin Securities given on Tuesday, October 20. The firm earned “Neutral” rating on Thursday, September 3 by Griffin Securities.
According to Zacks Investment Research, “Unilife Corporation is a medical device company based in U.S., focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. The primary target customers for the Company’s products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife’s main product is the Unifill ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. Unilife Corporation has FDA-registered medical device manufacturing facilities in Pennsylvania.”
More notable recent Unilife Corp (NASDAQ:UNIS) news were published by: Prnewswire.com which released: “Unilife Corporation Provides Trading Update” on September 29, 2016, also Reuters.com with their article: “BRIEF-Unilife Corp announces receipt of delinquency letter from Nasdaq” published on September 23, 2016, Streetinsider.com published: “Unilife Corp. (UNIS) Receives Nasdaq Listing Notification” on September 23, 2016. More interesting news about Unilife Corp (NASDAQ:UNIS) were released by: Prnewswire.com and their article: “Unilife Corporation Announces Receipt of Delinquency Letter from NASDAQ …” published on September 23, 2016 as well as Streetinsider.com‘s news article titled: “Unilife Corp. (UNIS) Names New CEO; Updates on Cost Reduction Initiatives …” with publication date: July 28, 2016.
UNIS Company Profile
Unilife Corporation, incorporated on July 2, 2009, is a medical device maker and component supplier. The Firm is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Firm has a portfolio of product platforms, including pre-filled syringes, wearable injectors, insulin delivery systems, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies who are expected to supply them as drug-device combination products, pre-filled and ready for administration by end users, such as health-care providers or patients. Other of its products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a healthcare well-known provider or end user without having the device pre-filled by a pharmaceutical company.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.